Antibody-drug conjugates combine targeting antibodies with powerful cytotoxic payloads, but clinical performance increasingly depends on linker chemistry, drug-to-antibody ratio, payload properties and how the medicine behaves inside heterogeneous tumors.
The new regimen replaces conventional chemotherapy with a Trop-2-directed antibody-drug conjugate while retaining PD-1 blockade, offering longer disease control but leaving overall survival, sequencing and cost questions unresolved.
The decision gives clinicians a Trodelvy-based option for patients who cannot receive checkpoint inhibitors and a Trodelvy plus Keytruda regimen for PD-L1-positive disease. The immediate clinical impact is substantial, although immature overall-survival data, toxicity management and treatment cost will influence how rapidly the new pathways displace chemotherapy.
Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.
See how One Biosciences is using single-cell profiling to improve ADC biomarkers, patient selection and future companion diagnostics.
Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.
Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.
Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?